Bayer, Versant returns a $ 250M cell therapy startup on an attempt to create immuno-oncology therapies on shelf – Endpoints News
Back in 2014, Stephanie Tagliatela chose to take an early exit from her doctoral program after working in the Mark Bear Lab at MIT, where she specialized in synaptic connections between neuronal cells in the brain. She never finished that doctorate, but she and other MIT student Kartik Ramamoorthi – who were on the foundation team in Voyager – got away with some ideas for a gene therapy startup.
Today, five years later, she and Ramamoorthi take away a $ 104 million mega round designed to take the cumulative work at their preclinical formative stage for coded therapy in human studies. They have now raised $ 158 million since joining the Illuminas Bay Area incubator, and they believe they are stuck on track to do something unique in gene therapy.
Basic Subscription Required
Unlock this story immediately and join 53,700+ biopharma professionals to read Endpoints daily ̵[ads1]1; and it's free.
